Clinical trials: Clostridium Difficile Infection Recurrence
Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
The primary objective of the study is to determine whether dietary intervention to increase fiber and decrease fat reduces C. difficile infection recurrence in a cohort of oncology patients.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Clostridium Difficile Infection
- Trial name
- NCT04940468
- Testing
- Diet Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Colorado, Denver
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile Infection, Clostridioides Difficile Infection
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Faecal microbiota transplantation (FMT) is used for Clostridioides difficile infection (CDI) as part of an quality improvement initiative and conducted within the framework of Center for Faecal Microbiota Transplantation at…
- Trial name
- CEFTA (NCT03712722)
- Testing
- Faecal microbiota transplantation (FMT)
- Where
- Denmark
- Volunteers
- 2,000 people
- Sponsor
- University of Aarhus
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
This study evaluated the safety and efficacy of VE303 for participants with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C. difficile infections (rCDI).
- Conditions
- Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence
- Trial name
- CONSORTIUM (NCT03788434)
- Testing
- VE303
- Where
- 37 sites in United States, Canada
- Volunteers
- 79 people
- Sponsor
- Vedanta Biosciences, Inc.
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Treatment for Clostridium-difficile Infection With IMM529
This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.
- Trial name
- NCT03065374
- Testing
- IMM-529
- Where
- 2 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Immuron Ltd.
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care…
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT), Comparative Effectiveness of CDI Treatments
- Trial name
- STOP-CDI (NCT07120490)
- Testing
- FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment
- Volunteers
- 424 people
- Sponsor
- Medical University of Warsaw
Clostridium Difficile Infection, Health Care Associated Infection
Natural History of Clostridioides Difficile Infection
Aim: To investigate if host factors, such as composition and diversity of intestinal microbiota and/or genetic determinants, are associated with a higher risk of recurrence of Clostridioides difficile infection (CDI).
- Conditions
- Clostridium Difficile Infection, Health Care Associated Infection, Nosocomial Infection
- Trial name
- NCT04801862
- Where
- 15 sites in Spain
- Volunteers
- 750 people
- Sponsor
- Hospital Universitario de Valme
Clostridium Difficile Infection
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
The purpose of this research is to investigate the efficacy of transplanting screened donor fecal material in treating patients with recurrent Clostridium difficile infection.
- Trial name
- FMT (NCT02326636)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Irvine
Enterocolitis Clostridium Difficile Recurrent
FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff
Delivery of FMT by upper route, including gastroscopy, nasogastric/ nasojejunal tube, and lower route, including retention enema, sigmoidoscopy, or colonoscopy have all been utilized successfully.
- Trial name
- NCT02254811
- Testing
- Fecal Microbiota Transplant
- Where
- 2 sites in Canada
- Volunteers
- 116 people
- Sponsor
- University of Alberta
Clostridioides Difficile Infection
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C.
- Trial name
- NCT04675723
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Clostridiodies Difficile Infections
MTC Versus FMT in for RCDI
Investigating four different treatment of MTC or FMT
- Trial name
- NCT05911997
- Testing
- MTC 01, Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Clostridium Difficile Infections
Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma
The increasing inappropriate use of antimicrobials, in addition to increasing selective pressure and inducing environmental resistance, is also a risk factor for the development of Clostridioides difficile infection (CDI).
- Trial name
- NCT06107569
- Testing
- Fecal microbiota transplant (Promicrobioma), Antibiotic
- Volunteers
- 24 people
- Sponsor
- Hospital Universitario Evangelico de Curitiba
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
The purpose of this study is to see if stool transplant performed by colonoscopy is effective at treating recurrent Clostridium difficile (C. diff) infection of the colon.
- Trial name
- NCT03562741
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Krunal Patel
Clostridium Difficile Infection
Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm Strategies
The objective of the present study is to derive a high-risk R-ICD prediction rule and a prospective implementation of this prediction rule.
- Trial name
- Clostri_Score (NCT04187430)
- Testing
- Retrospective, Prospective
- Where
- Spain
- Volunteers
- 513 people
- Sponsor
- Emilio Bouza
Recurrent C. Difficile Infection
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
To establish optimal dosing of lyophilized Fecal microbiota transplantation (FMT) product in the treatment of recurrent C. difficile infection
- Trial name
- NCT03298048
- Testing
- Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- The University of Texas Health Science Center, Houston
Clostridium Difficile
Randomized Clinical Trial of Standard FMT Treatments
This is a single center, randomized, parallel assignment, double-blinded, efficacy and safety study to be conducted in subjects with recurrent C. difficile Infection (RCDI).
- Trial name
- FMT (NCT04729790)
- Testing
- PRIM-DJ2727
- Sponsor
- The University of Texas Health Science Center, Houston
Recurrent Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium…
- Trial name
- PUNCH CD (NCT01925417)
- Testing
- RBX2660 (microbiota suspension)
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rebiotix Inc.
Clostridium Difficile
Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection
The overarching objective of this study is to address the knowledge gap regarding the short-term and long-term safety of fecal microbiota transplants (FMT).
- Trial name
- STOOL (NCT02403622)
- Testing
- Fecal Microbiota Preparation
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Microbiome Health Research Institute
Clostridium Difficile Infection
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
A higher frequency of recurrences in the University Hospital of Cabueñes (HUCAB) than in other hospitals in our area, including Central University Hospital of Asturias (HUCA) has been found.
- Trial name
- NCT04259931
- Testing
- microbiome analysis
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario de Cabuenes
Clostridia Difficile Colitis
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides…
- Trial name
- TAPER-V2 (NCT07328971)
- Testing
- Fidaxomicin, Vancomycin capsule
- Where
- 2 sites in Canada
- Volunteers
- 500 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre